logo
‘My Father Told Me...': RFK Jr. Makes Wild Warning Undermining Expert Health Advice

‘My Father Told Me...': RFK Jr. Makes Wild Warning Undermining Expert Health Advice

Yahoo23-05-2025
Health and Human Services Secretary Robert F. Kennedy Jr. on Thursday said assessing health guidance is similar to researching baby strollers as a new mom, urging Americans to 'be skeptical of authority' while serving in a top Cabinet position.
CNN's Kaitlan Collins asked Kennedy if he stood by his earlier comment that people should not be taking medical advice from him, even though his job involves communicating health guidance and recommendations based on his department's expertise.
'Yeah, absolutely,' Kennedy said. 'I'm somebody who is not a physician... and they should also be skeptical about any medical advice. They need to do their own research.'
Kennedy added that when 'you're a mom, you do your own research on your baby carriage, on your baby bottles, on your baby formula,' suggesting a similar approach should be taken when assessing medical advice.
When Collins pointed out that most mothers do not have medical degrees and would rather rely on their physicians, Kennedy claimed that health experts in a democracy 'are subject to all kinds of biases.'
'One of the responsibilities of living in a democracy is to do your own research and to make up your own mind,' he added.
Kennedy also recalled a piece of advice from his father, suggesting it was relevant to their discussion.
'I would say, be skeptical of authority. My father told me that when I was a young kid, people in authority lie,' Kennedy said, baselessly claiming that 'critical thinking was shut down' during the COVID-19 pandemic.
Kennedy, a prominent vaccine skeptic, was nominated to serve in one of the country's top jobs by President Donald Trump, raising eyebrows during a House subcommittee hearing last week with his answer to a question about whether he would vaccinate his children against measles if they were still young.
'I don't think people should be taking advice, medical advice from me,' he said.
'I think if I answer that question directly that it will seem like I'm giving advice to other people, and I don't want to be doing that,' he continued.
Kennedy, though, has not held back from lending credence to debunked conspiracy theories, including falsely suggesting that vaccines are linked to autism.
While his Making America Healthy Again report, released on Thursday, did not touch on that specific claim, it still hinted that the growth of the immunization schedule for children may be detrimental to them, even though childhood vaccination saves millions of lives every year.
'Vaccines benefit children by protecting them from infectious diseases. But as with any medicine, vaccines can have side effects that must be balanced against their benefits,' the report reads. 'Parents should be fully informed of the benefits and risks of vaccines.'
RFK Jr.'s MAHA Report Goes After Vaccines, Prescription Meds, Food Supply
RFK Jr.'s MAHA Report Raises Concerns About Vaccines, U.S. Foods And Prescription Drugs
RFK Jr. Has A Meltdown After Democrat Asks Him 1 Simple Question
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR

Yahoo

time16 minutes ago

  • Yahoo

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets

Why would Trump and Intel want to work together: Opening Bid top takeaway
Why would Trump and Intel want to work together: Opening Bid top takeaway

Yahoo

time16 minutes ago

  • Yahoo

Why would Trump and Intel want to work together: Opening Bid top takeaway

Investors are in wait-and-see mode. Fed watchers have had quite a week, getting a hot Producer Price Index, a tame Consumer Price Index, and solid retail sales data out today. As it stands, markets are still betting on that September rate cut from the Jerome Powell-led Federal Reserve. There have been a few earnings stumbles in CoreWeave (CRWV), Applied Materials (AMAT), and Cava (CAVA), but a few bright spots from the likes of Cisco (CSCO). The Bullish (BLSH) IPO saw an enthusiastic response. And now markets cast their gaze to the highly anticipated meeting today between President Trump and his Russian counterpart, Vladimir Putin. The outcome of this meeting could have a host of surprises that bullish investors haven't even thought about! Stock analysis: Intel The Trump administration is reportedly in talks to have the US government take a stake in Intel (INTC). An Intel spokesperson didn't comment directly on this to me, but offered this: "Intel is deeply committed to supporting President Trump's efforts to strengthen U.S. technology and manufacturing leadership. We look forward to continuing our work with the Trump Administration to advance these shared priorities, but we are not going to comment on rumors or speculation.' The questions here are numerous. Why would the administration even want a stake in an Intel that is far behind chief rivals Nvidia (NVDA) and Advanced Micro Devices (AMD)? I encourage Trump to compare Nvidia's earnings report on Aug. 27 to the last disaster from Intel a few weeks ago. The president isn't known to hitch his ride to losers. Intel has been a loser and may stay that way in the chip game for some time. Then again, why would Intel want to get in bed with the government when embattled CEO Lip-Bu Tan and the board must act quickly to reorganize the company? I find it hard to believe the government will be a quiet minority shareholder! Intel has billions in cash and doesn't need the money that comes with terms from any government deal. There is a lot at stake here, as Intel should be a beacon of US chip-making, not the punching bag in tech circles. The company's financials have taken a major hit, with sales down for more than three straight years and earnings evaporating in the process. "[A stake would] be a big step for Intel, but right now Intel is on a horse and buggy compared to the Godfather of AI Jensen [Huang] and Nvidia," Wedbush tech analyst Dan Ives told me. Roundtable analysis: More tech When a Wall Street analyst who has been a bear on a stock for a while suddenly issues an upgrade, it always catches my attention. Today, we have that situation on Salesforce (CRM). DA Davidson analyst Gil Luria lifted his rating on Salesforce to Neutral from Underperform. Luria said investor sentiment has declined sharply on Salesforce in recent months as questions mount around the company's acquisition strategy and near-term margins. But what may not be factored into the stock is new activist investor activity, Luria said. Luria pointed out that noted activist investor Starboard Value — led by Jeff Smith — increased its stake in Salesforce by 47% this quarter, according to new 13F filings. Starboard pushed for big changes at Salesforce three years ago, which ultimately led to a new focus on margin expansion by CEO and co-founder Marc Benioff. Luria said, "We believe this is a signal there will be another round of investor activism and increased pressure on management to refocus on growth of the core business, additional margin expansion and hold off on dilutive M&A." Meanwhile, Warren Buffett's Berkshire Hathaway sold 20 million shares of Apple (AAPL) during the period, according to a new 13F filing. Berkshire's Apple holdings remain its largest equity stake by market value, despite dropping by about $9.2 billion in the second quarter. Is Buffett signaling he is concerned about Apple's tariff exposure? Perhaps. After all, Apple did warn tariffs would hit its profits by $1.1 billion in the current quarter. Brian Sozzi is Yahoo Finance's Executive Editor and a member of Yahoo Finance's editorial leadership team. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Over two-thirds of Vermonters disapprove of Trump, the most of any state: See recent polls
Over two-thirds of Vermonters disapprove of Trump, the most of any state: See recent polls

Yahoo

time16 minutes ago

  • Yahoo

Over two-thirds of Vermonters disapprove of Trump, the most of any state: See recent polls

Out of all 50 states, President Donald Trump is the least popular in Vermont, a new poll reveals. According to an Aug. 12 update from Morning Consult, which gathers polls over the course of three months to get a look at state-level data among registered voters, Trump has the lowest approval rating in the country in Vermont. There, he has a net approval rating of -32, with 64% disapproving of his job performance. This aligns with polls taken earlier this year, too: a University of New Hampshire Survey Center poll conducted in June found Trump's net approval in Vermont at -41. Trump isn't popular in any of the New England states: the poll found Massachusetts was tied with Maryland for the second lowest net approval nationally with -26. Trump saw his highest approval in New England in Maine: -14. What is Trump's approval rating in New England? According to Morning Consult, this is Trump's net approval rating in each New England state: Connecticut: -19 Maine: -14 Massachusetts: -26 New Hampshire: -16 Rhode Island: -21 Vermont: -32 Where is Trump the most popular? Trump's approval rating is above water in 27 states, according to Morning Consult. The poll found him to be most popular in Wyoming, where 66% of voters approve of his job performance. What is Trump's approval rating overall? An average of recent polls from the New York Times shows that Trump's approval rating as of Aug. 14 is 44%, with 53% disapproving of his performance. This average has remained largely steady over the past month, but some individual polls have shown his support dropping to near-record lows as voters seem frustrated with Trump's August tariffs and his sweeping budget bill passed in early July. What is Trump's current presidential approval rating?Disapprove +22 (38% approve, 60% disapprove) Poll taken Aug. 4-10 3,505 registered votersDisapprove +12 (42% approve, 54% disapprove) Poll taken Aug. 9-11 1,635 adults Hart Research Associates/Public Opinion Strategies Disapprove +5 (46% approve, 51% disapprove) Poll taken July 29 – Aug. 3 1,000 adultsDisapprove +16 (40% approve, 56% disapprove) Poll taken July 25-27 1,023 adults1,400 registered voters Disapprove +1 (46% approve, 47% disapprove) Poll taken July 21-22 Contributing: Kinsey Crowley This article originally appeared on Burlington Free Press: Trump's approval rating is lowest in Vermont, poll says

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store